NASDAQ:IMTX

Immatics - IMTX Stock Forecast, Price & News

$8.73

+0.03 (+0.34%)

(As of 02/7/2023 04:08 PM ET)

Add

Compare

Today's Range: $8.55
▼
$8.81
50-Day Range: $7.81
▼
$11.36
52-Week Range: $5.75
▼
$13.60

Volume: 173,421 shs
Average Volume: 229,701 shs
Market Capitalization: $665.49 million

P/E Ratio: 13.03
Dividend Yield: N/A
Price Target: $27.00

Institutional Ownership

Immatics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 209.6% Upside
$27.00 Price Target
Short Interest: Bearish
4.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.59 to ($1.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

811th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

130th out of 168 stocks

3.5

Analyst's Opinion

Consensus Rating
Immatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.00, Immatics has a forecasted upside of 209.6% from its current price of $8.72.
Amount of Analyst Coverage
Immatics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.91% of the float of Immatics has been sold short.
Short Interest Ratio / Days to Cover
Immatics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Immatics has recently decreased by 2.40%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Immatics does not currently pay a dividend.
Dividend Growth
Immatics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMTX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Immatics this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immatics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 29.05% of the stock of Immatics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Immatics are expected to decrease in the coming year, from $0.59 to ($1.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immatics is 13.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immatics is 13.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.80.
Price to Book Value per Share Ratio
Immatics has a P/B Ratio of 19.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immatics (NASDAQ:IMTX) Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Stock News Headlines

February 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Immatics (IMTX)

February 1, 2023 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Sees Large Volume Increase

February 7, 2023 | Wall Street Watch Dogs (Ad)

The #1 Energy Stock to Buy

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

December 17, 2022 | finance.yahoo.com

Immatics N.V.'s (NASDAQ:IMTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

December 16, 2022 | reuters.com

IMTX.O - Immatics NV | Stock Price & Latest News | Reuters

November 17, 2022 | finance.yahoo.com

Immatics Announces Third Quarter 2022 Financial Results and Business Update

November 17, 2022 | finance.yahoo.com

Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

October 31, 2022 | finance.yahoo.com

Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?

February 7, 2023 | Wall Street Watch Dogs (Ad)

The #1 Energy Stock to Buy

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

October 14, 2022 | msn.com

Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?

October 10, 2022 | nz.finance.yahoo.com

Shareholders in Immatics (NASDAQ:IMTX) are in the red if they invested a year ago

October 10, 2022 | seekingalpha.com

Hot Stocks: Macau stocks drop on COVID worries; EDU, TAL plunge; AXNX downgrade; IMTX rises on clinical data

October 10, 2022 | msn.com

Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers

October 10, 2022 | finance.yahoo.com

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

October 10, 2022 | finance.yahoo.com

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

September 27, 2022 | seekingalpha.com

IMTX Immatics N.V.

September 13, 2022 | nasdaq.com

Further weakness as Immatics (NASDAQ:IMTX) drops 11% this week, taking one-year losses to 26%

August 29, 2022 | reuters.com

IMTX.OQ - Immatics NV | Stock Price & Latest News | Reuters

August 24, 2022 | finanznachrichten.de

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME

August 23, 2022 | finance.yahoo.com

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

August 12, 2022 | finance.yahoo.com

Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a Bet

August 9, 2022 | nz.finance.yahoo.com

Immatics Announces Second Quarter 2022 Financial Results and Business Update

July 20, 2022 | nasdaq.com

Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?

June 25, 2022 | finance.yahoo.com

Do Its Financials Have Any Role To Play In Driving Immatics N.V.'s (NASDAQ:IMTX) Stock Up Recently?

June 17, 2022 | morningstar.com

Immatics NV Ordinary Shares - Stock Chart

June 9, 2022 | seekingalpha.com

Editas in licensing deal with Immatics for cancer therapies

June 2, 2022 | seekingalpha.com

Immatics GAAP EPS of €1.35, revenue of €102.91M

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Company Calendar

Last Earnings: 11/17/2022
Today: 2/07/2023
Next Earnings (Estimated): 3/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMTX
CUSIP: N/A
CIK: 1809196
Web: www.immatics.com
Phone: 49-7071-539-7700
Fax: N/A
Employees: 188
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.00
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $26.00
Forecasted Upside/Downside: +209.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.67
Trailing P/E Ratio: 13.03
Forward P/E Ratio: 14.80
P/E Growth: N/A
Net Income: $-110,430,000.00
Net Margins: 24.60%
Pretax Margin: 22.98%
Return on Equity: 40.49%
Return on Assets: 12.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.60
Quick Ratio: 2.60

Sales & Book Value

Annual Sales: $41.13 million
Price / Sales: 16.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: 19.40

Miscellaneous

Outstanding Shares: 76,230,000
Free Float: N/A
Market Cap: $665.49 million
Optionable: Not Optionable
Beta: 0.49

Key Executives

Dr. Harpreet Singh Ph.D. (Age 47)
CEO, MD, Member of Management Board & Supervisory Director

Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board

Dr. Toni Weinschenk Ph.D. (Age 49)
Co-Founder & Chief Innovation Officer

Mr. Arnd Christ MBA (Age 56)
Chief Financial Officer

Mr. Steffen Walter Ph.D. (Age 46)
Chief Technology Officer

Mr. Edward A. Sturchio
Gen. Counsel & Sec.

Ms. Anja Heuer B.Sc.
Director of Corp. Communications

Ms. Tamara Louw M.B.A.
P.H.R., Sr. Director of HR

Dr. Carsten Reinhardt M.D. (Age 55)
Ph.D., Chief Devel. Officer

Dr. Rainer Kramer Ph.D. (Age 57)
Chief Bus. Officer & Site Head Munich

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

IMTX Stock - Frequently Asked Questions

Should I buy or sell Immatics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings or view top-rated stocks.
What is Immatics' stock price forecast for 2023?: 2 Wall Street analysts have issued twelve-month price targets for Immatics' shares. Their IMTX share price forecasts range from $26.00 to $28.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price.
View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts.
How have IMTX shares performed in 2023?: Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX shares have decreased by 0.1% and is now trading at $8.70.
View the best growth stocks for 2023 here.
When is Immatics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our IMTX earnings forecast.
How were Immatics' earnings last quarter?: Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Thursday, November, 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. The firm had revenue of $15.18 million for the quarter, compared to analysts' expectations of $13.36 million. Immatics had a net margin of 24.60% and a trailing twelve-month return on equity of 40.49%.

What other stocks do shareholders of Immatics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).
What is Immatics' stock symbol?: Immatics trades on the NASDAQ under the ticker symbol "IMTX."
How do I buy shares of Immatics?: Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immatics' stock price today?: One share of IMTX stock can currently be purchased for approximately $8.70.
How much money does Immatics make?: Immatics (NASDAQ:IMTX) has a market capitalization of $663.20 million and generates $41.13 million in revenue each year. The company earns $-110,430,000.00 in net income (profit) each year or $0.67 on an earnings per share basis.
How many employees does Immatics have?: The company employs 188 workers across the globe.
How can I contact Immatics?: Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 49-7071-539-7700.

This page (NASDAQ:IMTX) was last updated on 2/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immatics - IMTX Stock Forecast, Price & News

Immatics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immatics (NASDAQ:IMTX) Stock

IMTX Stock News Headlines

IMTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMTX Stock - Frequently Asked Questions

Overall MarketRank^™